Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931752 | 0.92 | LMNA (0.39) | LMNAGAAMEN1NPC1MAPT | |
| SCHEMBL2929641 | 0.91 | KCNH2 (0.41) | LMNAGAAMEN1NPC1MAPT | |
| SCHEMBL2930571 | 0.89 | OPRL1 (0.38) | LMNAGAAMEN1NPC1MAPT | |
| SCHEMBL2930795 | 0.88 | PIK3CA (0.43) | LMNAGAAMEN1NPC1MAPT | |
| SCHEMBL2931431 | 0.88 | PRKCQ (0.42) | LMNAGAAMEN1NPC1MAPT | |
| SCHEMBL2926394 | 0.88 | PRKCA (0.38) | LMNAGAAMEN1NPC1MAPT | |
| SCHEMBL2926396 | 0.79 | RAF1 (0.44) | LMNAGAAMAPT | |
| SCHEMBL2930096 | 0.78 | TBK1 (0.35) | TBK1 | |
| SCHEMBL2929442 | 0.77 | GAA (0.41) | LMNAGAAMEN1NPC1MAPT | |
| SCHEMBL2924961 | 0.75 | LMNA (0.39) | LMNAGAAMEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | F12 2441/4885LMNA 1520/4885GAA 1732/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | F12 2441/4885LMNA 1520/4885GAA 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.